Company Profile

OncoImmune Inc
Profile last edited on: 12/22/2020      CAGE: 3U7C0      UEI: G8WAHQ82DVC4

Business Identifier: Molecular therapeutics for treatment of cancers and autoimmune disease
Year Founded
First Award
Latest Award
Program Status
Active (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

9430 Key West Avenue Unit 113
Rockville, MD 20852
   (301) 557-9119
Location: Multiple
Congr. District: 06
County: Montgomery

Public Profile

Rumoured for some time, in November 2020 it was announced that Merck had acquired OncoImmune in a cash transaction soon after the firm revealed positive top-line findings from an interim efficacy analysis of a Phase 3 study evaluating its lead therapeutic candidate CD24Fc for the treatment of patients with severe and critical COVID-19. Formerly located in Michigan and having close ties to University of Michigan, Ann Arbor before relocating to Rockville, MD., long-time SBIR Involved OncoImmune Inc. is a clinical-stage biotechnology company initially focused on developing and commercializing biopharmaceuticals for the treatment of cancer and autoimmune disease. Including protein therapeutics, monoclonal antibodies, and small molecular drugs, the firm has been developing solutions for a variety of autoimmune and infectious diseases including multiple sclerosis, rheumatoid arthritis, sepsis, tuberous sclerosis, acute myeloid leukemia and diabetic nephropathy. The firm has moved their lead product - CD24Fc - from a basic concept into clinical trials. CD24Fc has a novel mechanism of action that is applicable to a number of autoimmune diseases and has shown good safety and tolerability in a Phase I clinical trial in healthy volunteers. In two Phase 2 trials in GVHD, the firm reported having observed clinical activity. Similar clinical activity was observed in the Phase 3 trial in COVID-19. prior to Merck acquisition (late 2020) OncoImmune had also been preparing for a Phase II clinical trial of CD24Fc for the prophylactic treatment of acute Graft versus Host Disease (GvHD).

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Key People / Management

  Yang Liu -- Co-Founder, President and Chief Scientific Officer

  Randal Chinnock

  Martin Davenport -- COO

  Martin Devenport -- Chief Operating Officer

  Dexing Fang -- Research Scientist

  Kun-Liang Guan -- Founder

  Mark Kubik -- Chief Business Officer

  Michael C Luecke

  Ping Qiu

  Weng Tao -- Head of Regulatory Affairs

  Jeff Wilkins -- Board of Directors

  Liu Xingluo

  Li-Hui Xu

  Ming D You -- Founder

  Pan Zheng -- Co-Founder, Senior Vice President and Chief Medical Officer

  Qunmin Zhou